Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$8.67 USD

8.67
284,110

0.00 (0.00%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $8.66 -0.01 (-0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Insulet (PODD) Beats Earnings and Revenue Estimates in Q4

by Zacks Equity Research

The year-over-year improvement in Insulet's (PODD) Q4 results on solid uptake of Omnipod system in the United States is encouraging. The company also gains from direct European operations.

Zacks Equity Research

Fresenius Medical (FMS) Earnings Beat, Revenues Miss in Q4

by Zacks Equity Research

Fresenius Medical (FMS) sees higher Q4 revenues in EMEA and Asia Pacific regions.

Zacks Equity Research

Masimo (MASI) Q4 Earnings and Revenues Beat, Guidance Solid

by Zacks Equity Research

Masimo (MASI) sees an increase in shipments of noninvasive technology in Q4.

Zacks Equity Research

Teleflex (TFX) Q4 Earnings Miss Estimates, Margins Rise

by Zacks Equity Research

In Q4, Teleflex (TFX) registers strong growth in PICC, visual navigation products and EZ-IO.

Zacks Equity Research

Integra's (IART) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Strength in the U.S. Codman Specialty Surgical business drives Integra LifeSciences' (IART) top line in Q4.

Zacks Equity Research

DexCom's (DXCM) Q4 Earnings Beat, International Revenues Up

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter 2018 results benefit from strong contributions from the Sensor, Transmitter and Receiver segments.

Zacks Equity Research

Chemed (CHE) Q4 Earnings Beat Estimates, Gross Margin Falls

by Zacks Equity Research

Chemed's (CHE) Q4 revenues grow across key segments.

Zacks Equity Research

Allscripts (MDRX) Q4 Earnings Lag Estimates, Bookings Up Y/Y

by Zacks Equity Research

Significant year-over-year rise in bookings favors Allscripts' (MDRX) fourth-quarter 2018 results.

Zacks Equity Research

Integer Holdings' (ITGR) Q4 Earnings Beat, '19 View Strong

by Zacks Equity Research

Integer Holdings (ITGR) gains from the core Medical Sales segment's impressive performance in fourth-quarter 2018.

Zacks Equity Research

NuVasive (NUVA) Q4 Earnings Beat Estimates, Margins Fall

by Zacks Equity Research

NuVasive (NUVA) reports growth in revenues across all key operating segments in the fourth quarter of 2018.

Zacks Equity Research

Genomic Health (GHDX) Q4 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Genomic Health's (GHDX) year-over-year rise in revenues, driven by a solid uptick in the United States and internationally, makes us optimistic about the stock.

Zacks Equity Research

CVS Health's (CVS) Q4 Earnings Top Estimates, Margins Up

by Zacks Equity Research

CVS Health's (CVS) recently introduced Health Care Benefits segment following the Aetna acquisition holds immense promise.

Zacks Equity Research

Henry Schein's (HSIC) Q4 Earnings Top, Revenues Lag Estimates

by Zacks Equity Research

Strength in Henry Schein's (HSIC) global Medical and Technology and Value-added Services businesses in Q4 is encouraging.

Zacks Equity Research

Medtronic (MDT) Beats on Q3 Earnings, Gross Margin Down

by Zacks Equity Research

Medtronic (MDT) demonstrates improved performances at CER based on growth in most of the business segments and all geographies.

Zacks Equity Research

Ecolab (ECL) Earnings and Revenues Match Estimates in Q4

by Zacks Equity Research

Ecolab (ECL) sees solid segmental gains in Q4.

Zacks Equity Research

Cryolife (CRY) Earnings Miss, Revenues Top Estimates in Q4

by Zacks Equity Research

Cryolife (CRY) revenues increase year over year across all geographies and major segments.

Zacks Equity Research

Quidel (QDEL) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Quidel's (QDEL) flagship Triage sees strong growth in China in Q4.

Zacks Equity Research

Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down

by Zacks Equity Research

In recent times, Quest Diagnostics (DGX) is facing several reimbursement issues which have hurt revenues.

Zacks Equity Research

Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines

by Zacks Equity Research

Bio-Techne (TECH) sees increase in revenues across key segments.

Zacks Equity Research

DaVita (DVA) Q4 Earnings Beat and Revenues Miss Estimates

by Zacks Equity Research

DaVita's (DVA) Q4 results gain from increasing dialysis services in and outside the United States.

Zacks Equity Research

Medidata (MDSO) Q4 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

Medidata (MDSO) gains from solid segmental performance in Q4.

Zacks Equity Research

Bruker (BRKR) Q4 Earnings In Line, Margin Growth Strong

by Zacks Equity Research

Bruker (BRKR) witnesses a sturdy organic revenue uptick riding on the strength of Bruker Scientific Instruments (BSI) and BEST segments.

Zacks Equity Research

STERIS (STE) Q3 Earnings In Line, Revenues Beat Estimates

by Zacks Equity Research

STERIS (STE) continues to gain from strength in all business segments in Q3.

Zacks Equity Research

IRADIMED (IRMD) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

IRADIMED (IRMD) reports growth across all operating segments and geographies

Zacks Equity Research

Phirbo (PAHC) Q2 Earnings Lag Estimates, Operating Margin Up

by Zacks Equity Research

Phirbo (PAHC) witnesses significant growth in core segment revenues in Q2.